Iatrogenic lung disease:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2004
|
| Schriftenreihe: | Clinics in chest medicine
25,1 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIX, 236 S. Ill. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV018008894 | ||
| 003 | DE-604 | ||
| 005 | 20150218 | ||
| 007 | t | ||
| 008 | 040415s2004 a||| |||| 00||| eng d | ||
| 035 | |a (OCoLC)54833270 | ||
| 035 | |a (DE-599)BVBBV018008894 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 050 | 0 | |a RC941 | |
| 245 | 1 | 0 | |a Iatrogenic lung disease |c guest ed. Philippe Camus ... |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2004 | |
| 300 | |a XIX, 236 S. |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Clinics in chest medicine |v 25,1 | |
| 650 | 7 | |a Iatrogene ziekten |2 gtt | |
| 650 | 7 | |a Longziekten |2 gtt | |
| 650 | 4 | |a Bone Marrow Transplantation |x adverse effects | |
| 650 | 4 | |a Drug Therapy |x adverse effects | |
| 650 | 4 | |a Drug-induced disorders | |
| 650 | 4 | |a Iatrogenic Disease | |
| 650 | 4 | |a Iatrogenic disease | |
| 650 | 4 | |a Lung Diseases | |
| 650 | 4 | |a Lung diseases |x Complications | |
| 650 | 4 | |a Pulmonary toxicology | |
| 650 | 4 | |a Radiotherapy |x adverse effects | |
| 650 | 4 | |a Respiratory Tract Diseases |x etiology | |
| 650 | 4 | |a Street Drugs |x adverse effects | |
| 650 | 4 | |a Thoracic Neoplasms |x etiology | |
| 700 | 1 | |a Camus, Philippe |e Sonstige |4 oth | |
| 830 | 0 | |a Clinics in chest medicine |v 25,1 |w (DE-604)BV000001084 |9 25,1 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010781367&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-010781367 | ||
Datensatz im Suchindex
| _version_ | 1804130624920879104 |
|---|---|
| adam_text | CONTENTS
Preface xiii
Philippe Camus and Edward C. Rosenow HI
Mechanisms in Pulmonary Toxicology 1
Luc M. Delaunois
Specific accumulation and biotransformation of drugs cause cell injury in the lung.
Evoked mechanisms are oxidative injury, direct cytotoxic effects, intracellular deposition
of phospholipids, and immune reaction. Individual susceptibility can be due to geneti¬
cally determined metabolic idiosyncrasy or to immune mediated hypersensitivity.
Chest Imaging in Iatrogenic Respiratory Disease 15
Rebecca M. Lindell and Thomas E. Hartman
Iatrogenic respiratory disease is an important cause of patient morbidity and mortality.
Clinical and radiologic findings are nonspecific and diagnosis can be difficult. Therefore,
it is important for physicians to be familiar with the iatrogenic diseases for which their
patients are at risk, as well as their common radiologic appearances. Causes of iatrogenic
respiratory disease include drugs, transplantation, radiation, transfusion, or other mis¬
cellaneous therapies.
Bronchoalveolar Lavage in Drug Induced Lung Disease 25
Ulrich Costabel, Esra Uzaslan, and Josune Guzman
This article reviews some technical aspects of bronchoalveolar lavage (BAL), gives
an overview on the use of BAL in the differential diagnosis of interstitial lung dis¬
ease, and concludes with a detailed description of the BAL findings in drug induced
lung disease.
Pathologic Characteristics of Drug Induced Lung Disease 37
Douglas B. Flieder and William D. Travis
The surgical pathologist s approach to diagnosing a pulmonary drug reaction requires
the synthesis of clinical and radiographic information with morphologic findings.
Bronchoalveolar lavage and transbronchial biopsy samples are most useful in excluding
infection, whereas surgical (open or thoracoscopic) lung biopsies demonstrate pathologic
VOLUME 25 • NUMBER 1 • MARCH 2004 vii
patterns that are associated with particular drug toxicities. Interstitial pneumonias are
most common but airway, airspace, and vascular pathology, in addition to pleural
disease, may occur. Accurate recognition of histologic patterns and awareness of which
patterns occur with particular drugs may be helpful clues that aid in the diagnosis of
adverse drug reactions.
Infiltrative Lung Disease Due to Noncytotoxic Agents 47
Brion J. Lock, Michael Eggert, and J. Allen D. Cooper, Jr
Reactions to certain drugs that are used in the treatment of benign disorders can result
in pulmonary parenchymal disease. Although amiodarone is the most recognized drug
to cause pulmonary reactions, antirheumatic agents, including methotrexate, penicil
lamine, and gold salts, also cause these reactions. This article discusses the pulmonary
adverse effects of antirheumatic agents and drugs, other than amiodarone, that are used
in the treatment of benign conditions.
Chemotherapy Induced Lung Disease 53
Andrew H. Limper
The lung has significant susceptibility to injury from a variety of chemotherapeutic
agents. The clinician must be familiar with classic chemotherapeutic agents with well
described pulmonary toxicities and also must be vigilant that a host of new agents
may exert emerging adverse effects on lung function. The diagnosis of chemotherapy
associated lung disease remains an exclusionary process, particularly with respect to
usual and atypical infections as well as recurrence of the underlying neoplastic
process in these immunocompromised patients. In many instances, chemotherapy
associated lung disease may respond to withdrawal of the offending agent and to the
judicious application of corticosteroid therapy in selected patients.
Amiodarone Pulmonary Toxicity 65
Philippe Camus, William J. Martin II, and Edward C. Rosenow III
The amount of literature on amiodarone pulmonary toxicity (APT) peaked in 1983 1984
with several hundred cases reported cumulatively, and declined thereafter. Since the mid
1990s, publications have increased, which suggests that APT remains a current problem
in clinical practice. Amiodarone remains difficult to diagnose noninvasively, and
although the outcome is good in the majority of patients, not all cases of APT can be con¬
trolled satisfactorily.
Drug Induced Eosinophilic Lung Disease 77
James N. Allen
Eosinophilic lung disease can present as pulmonary infiltrates with blood eosinophilia
or as increased eosinophils in bronchoalveolar lavage or histologic specimens.
Prescribed medications, over the counter medications, herbal remedies, and street drugs
can cause drug induced eosinophilic lung disease. Several drugs have been reported to
cause eosinophilic lung disease but certain drugs are more frequently implicated than
others. The diagnosis primarily is based on the history and physical examination as well
as exclusion of other eosinophilic lung diseases.
viii CONTENTS
Drug Induced Bronchiolitis Obliterans Organizing Pneumonia 89
Gary R. Epler
Several classes of medications cause the bronchiolitis obliterans organizing pneumonia
(BOOP) reaction, including the antimicrobials, anticancer agents, cardiac agents, and
anti inflammatory agents. The BOOP reaction represents an inflammatory response
of the lung, and, therefore, is generally reversible by drug cessation or corticosteroid
therapy. Organizing pneumonia is a general term that includes BOOP. This article
includes a review of the clinical findings, radiographic abnormalities, physiologic find¬
ings, and management of drug induced BOOP.
Drug Induced Pulmonary Edema and Acute Respiratory Distress Syndrome 95
Teofilo Lee Chiong, Jr and Richard A. Matthay
Noncardiogenic pulmonary edema, and, to a lesser extent, acute respiratory distress
syndrome (ARDS), are common clinical manifestations of drug induced lung diseases.
Clinical features and radiographic appearances are generally indistinguishable from
other causes of pulmonary edema and ARDS. Typical manifestations include dyspnea,
chest discomfort, tachypnea, and hypoxemia. Chest radiographs commonly reveal
interstitial and alveolar filling infiltrates. Unlike pulmonary edema that is due to con¬
gestive heart failure, cardiomegaly and pulmonary vascular redistribution are generally
absent in cases that are drug related. Rare cases of drug induced myocarditis with heart
failure and pulmonary edema have been described. Results from laboratory evaluation
and respiratory function tests are nonspecific.
Pulmonary Injury from Transfusion Related Acute Lung Injury 105
Patricia M. Kopko and Mark A. Popovsky
Transfusion related acute lung injury (TRALI) can be a life threatening complication of
transfusion. In its severe form, it is clinically indistinguishable from acute respiratory
distress syndrome. Symptoms typically begin within 4 hours of transfusion. TRALI has
been reported after transfusion of all plasma containing blood components. TRALI is
associated with antibodies to white blood cells and biologically active lipids in trans¬
fused blood components.
Drug Induced Airway Diseases 113
K. Suresh Babu and Benjamin G. Marshall
Drug induced airway disease can manifest as bronchoconstriction, which also can be a fea¬
ture of a drug induced anaphylactic reaction, cough, or obliterative bronchiolitis. Some
symptoms are trivial (eg, cough induced by angiotensin converting enzyme inhibitors),
whereas others are life threatening (eg, drug induced anaphylaxis). With new drugs being
added to the therapeutic armamentarium, a close watch is essential to identify drug
induced adverse reactions to prevent and to develop a management strategy.
Pulmonary Hypertension as a Result of Drug Therapy 123
Tim Higenbottam, Liz Laude, Celia Emery, and Mohamed Essener
This article reviews the history of anorectic pulmonary arterial hypertension and
considers the mechanisms. The article also includes those drugs where the strength of
association is less strong but where useful learning may be gained.
CONTENTS ix
Drug Induced Diffuse Alveolar Hemorrhage Syndromes and Vasculitis 133
Marvin I. Schwarz and Andrew P. Fontenot
Current and past drug intake is essential when evaluating a patient who has diffuse
alveolar hemorrhage (DAH). Simple treatments, such as reversal of a coagulation defect
or withdrawal of the drug, can reverse a life threatening situation.
Drug Induced Pleural Disease 141
John T. Huggins and Steven A. Sahn
Drug induced pleural disease is an uncommon phenomenon, especially compared with
drug induced parenchymal disease. Approximately 30 drugs are believed to be defini¬
tively or probably causative of pleural disease. In addition, six drugs are strongly asso¬
ciated with drug induced lupus. Drugs should always be considered as a potential
cause for an undiagnosed exudative effusion before proceeding with an extensive diag¬
nostic evaluation. Pleural fluid eosinophilia has been associated with eight medications
and its presence should alert the clinician as a possible cause of an undiagnosed exuda¬
tive pleural effusion X.
Iatrogenic Induced Dysfunction of the Neuromuscular Respiratory System 155
Thomas Similowski and Christian Straus
An adequate alveolar ventilation depends on the production, transmission, and execu¬
tion of an appropriate ventilatory command. Medical interventions, pharmacologic or
nonpharmacologic, can interfere with this process at any point (eg, anesthesia induced
ventilatory depression, phrenic nerve injury during topical cooling for cardiac surgery,
neuromuscular blockade, drug induced or upper abdominal surgery induced
diaphragmatic dysfunction with emphasis on corticosteroid induced myopathy) or at
multiple sites (eg, critical illness polyneuropathy). The clinical consequences of these
iatrogenic processes are variable but potentially severe, from dyspnea related exercise
limitation and orthopnea to delayed weaning from mechanical ventilation, ventilator
dependency, and death. The possibility of iatrogenic complications must be evoked in
the presence of hypoventilation or of a restrictive ventilatory defect with clear lungs on
chest radiograph, or unexplained dyspnea, exactly as it must be evoked among the diag¬
nostic hypotheses of interstitial lung disease.
Pulmonary Complications of Radiation Therapy 167
Raymond P. Abratt, Graeme W. Morgan, Gerard Silvestri, and Paul Willcox
Acute radiation pneumonitis occurs within 1 or 2 months after commencing fractionated
irradiation and usually responds to treatment with steroids. Late radiation toxicity is
characterized by pulmonary fibrosis that typically begins 6 to 12 months after irradia¬
tion that may result in progressive dyspnea and mortality. Patient morbidity depends on
factors such as baseline lung functions and the volume of lung irradiated above a
threshold radiation dose.
Drug Induced Pulmonary Infection 179
Dorothy A. White
Immunosuppressive drugs are used to treat autoimmune diseases or prevent organ
rejection and graft versus host disease. As expected, these drugs have been associated
with development of infections. This article reviews the relationship of immunosup¬
pressive drugs to specific infections and the prophylactic strategies that are available. In
x CONTENTS
addition, the newer cancer drugs that are targeted to lymphocytes with resultant deple¬
tion and a propensity to infection are discussed.
Pulmonary Complications in Bone Marrow Transplantation: A Practical Approach
to Diagnosis and Treatment 189
Kenneth T. Yen, Augustine S. Lee, Michael J. Krowka, and Charles D. Burger
Pulmonary complications occur in 40% to 60% of recipients of bone marrow trans¬
plants, account for more than 90% of mortality, and develop during identifiable phases.
Phase 1 (Days 1 30) includes pulmonary edema; diffuse alveolar hemorrhage; and var¬
ious bacterial, fungal, and viral infections; Phase 2 (Days 31 100) usually requires a dis¬
tinction between cytomegalovirus pneumonitis and idiopathic pneumonia syndrome;
and Phase 3 (Day 100+) includes complications that are due to chronic graft versus host
disease and associated bronchiolitis obliterans. The spectrum of pulmonary complica¬
tions has been influenced by changes in transplantation technique, prophylactic treat¬
ment for infections, and the use of new chemotherapeutic agents that contribute to lung
injury. Nonetheless, infections remain a leading cause of morbidity and mortality. The
most serious complications result in respiratory failure, for which the prognosis has not
improved significantly over the last 2 decades. In this article, we describe our algorith¬
mic approach to the diagnosis and management of these complications.
Pulmonary Effects of Illicit Drug Use 203
Armand J. Wolff and Anne E. O Donnell
The lungs are unique in their exposure to the environment and the circulation; they are
susceptible to damage from illicit drugs that are used by intravenous injection and
inhalation. This article provides an update on the pulmonary effects of illicit drug use.
Therapy Induced Thoracic Malignancies 217
Lydia B. Zablotska, Anne H. Angevine, and Alfred I. Neugut
Cancer survivors in the United States are growing rapidly in number. A cancer patient s
survival is often the result of potentially carcinogenic treatments, such as radiation ther¬
apy or chemotherapy. As a result, the incidence, prevention, and management of thera¬
py induced second primary malignancies in long term cancer survivors is an issue of
increasing importance. Within the thorax, radiation therapy is more commonly the
cause of treatment related second primary tumors than is chemotherapy. This article
reviews the background of radiation carcinogenesis and presents the epidemiologic
evidence of therapy induced thoracic malignancies, particularly lung cancer,
esophageal cancer, and malignant pleural mesothelioma. Although no specific screen¬
ing recommendations for second primary malignancies of the thorax have been estab¬
lished, clinicians should note that patients who have a history of thoracic radiation
exposure, regardless of how remote, are at increased risk of developing new cancers.
Index 225
CONTENTS xi
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV018008894 |
| callnumber-first | R - Medicine |
| callnumber-label | RC941 |
| callnumber-raw | RC941 |
| callnumber-search | RC941 |
| callnumber-sort | RC 3941 |
| callnumber-subject | RC - Internal Medicine |
| ctrlnum | (OCoLC)54833270 (DE-599)BVBBV018008894 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01640nam a2200457 cb4500</leader><controlfield tag="001">BV018008894</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20150218 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">040415s2004 a||| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)54833270</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV018008894</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC941</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Iatrogenic lung disease</subfield><subfield code="c">guest ed. Philippe Camus ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIX, 236 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Clinics in chest medicine</subfield><subfield code="v">25,1</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Iatrogene ziekten</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Longziekten</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bone Marrow Transplantation</subfield><subfield code="x">adverse effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Therapy</subfield><subfield code="x">adverse effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug-induced disorders</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Iatrogenic Disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Iatrogenic disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung diseases</subfield><subfield code="x">Complications</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pulmonary toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiotherapy</subfield><subfield code="x">adverse effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory Tract Diseases</subfield><subfield code="x">etiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Street Drugs</subfield><subfield code="x">adverse effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thoracic Neoplasms</subfield><subfield code="x">etiology</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Camus, Philippe</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Clinics in chest medicine</subfield><subfield code="v">25,1</subfield><subfield code="w">(DE-604)BV000001084</subfield><subfield code="9">25,1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010781367&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-010781367</subfield></datafield></record></collection> |
| id | DE-604.BV018008894 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T19:24:00Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-010781367 |
| oclc_num | 54833270 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | XIX, 236 S. Ill. |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Saunders |
| record_format | marc |
| series | Clinics in chest medicine |
| series2 | Clinics in chest medicine |
| spelling | Iatrogenic lung disease guest ed. Philippe Camus ... Philadelphia [u.a.] Saunders 2004 XIX, 236 S. Ill. txt rdacontent n rdamedia nc rdacarrier Clinics in chest medicine 25,1 Iatrogene ziekten gtt Longziekten gtt Bone Marrow Transplantation adverse effects Drug Therapy adverse effects Drug-induced disorders Iatrogenic Disease Iatrogenic disease Lung Diseases Lung diseases Complications Pulmonary toxicology Radiotherapy adverse effects Respiratory Tract Diseases etiology Street Drugs adverse effects Thoracic Neoplasms etiology Camus, Philippe Sonstige oth Clinics in chest medicine 25,1 (DE-604)BV000001084 25,1 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010781367&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Iatrogenic lung disease Clinics in chest medicine Iatrogene ziekten gtt Longziekten gtt Bone Marrow Transplantation adverse effects Drug Therapy adverse effects Drug-induced disorders Iatrogenic Disease Iatrogenic disease Lung Diseases Lung diseases Complications Pulmonary toxicology Radiotherapy adverse effects Respiratory Tract Diseases etiology Street Drugs adverse effects Thoracic Neoplasms etiology |
| title | Iatrogenic lung disease |
| title_auth | Iatrogenic lung disease |
| title_exact_search | Iatrogenic lung disease |
| title_full | Iatrogenic lung disease guest ed. Philippe Camus ... |
| title_fullStr | Iatrogenic lung disease guest ed. Philippe Camus ... |
| title_full_unstemmed | Iatrogenic lung disease guest ed. Philippe Camus ... |
| title_short | Iatrogenic lung disease |
| title_sort | iatrogenic lung disease |
| topic | Iatrogene ziekten gtt Longziekten gtt Bone Marrow Transplantation adverse effects Drug Therapy adverse effects Drug-induced disorders Iatrogenic Disease Iatrogenic disease Lung Diseases Lung diseases Complications Pulmonary toxicology Radiotherapy adverse effects Respiratory Tract Diseases etiology Street Drugs adverse effects Thoracic Neoplasms etiology |
| topic_facet | Iatrogene ziekten Longziekten Bone Marrow Transplantation adverse effects Drug Therapy adverse effects Drug-induced disorders Iatrogenic Disease Iatrogenic disease Lung Diseases Lung diseases Complications Pulmonary toxicology Radiotherapy adverse effects Respiratory Tract Diseases etiology Street Drugs adverse effects Thoracic Neoplasms etiology |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010781367&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000001084 |
| work_keys_str_mv | AT camusphilippe iatrogeniclungdisease |